Background: Pediatric lung transplantation is a therapeutic option for children and adolescents with end‐stage lung disease. While it offers a chance to extend survival and improve physical health, the impact on health‐related quality of life (HRQOL) remains understudied. Methods: This observational study aimed to assess HRQOL in pediatric lung transplant recipients using the EuroQol questionnaire and additional self‐designed questions about school, employment, and housing situations. We compared the results to those in children and adolescents with end‐stage lung disease and investigated possible influencing determinants. Patients were included during routine clinical visits, starting at least 2 months post‐transplant. Data collection was from November 2016 to January 2023. Results: The study included 29 pediatric lung transplant recipients aged between 4 and 17 years at the time of first transplantation. Our findings show a good HRQOL after pediatric lung transplantation with a median EuroQol‐Score of 1.0, representing the best possible EuroQol‐Score, and a median visual analog scale (VAS) score of 93 out of 100. Most patients were engaged in employment or education, and they typically lived with their parents. HRQOL was superior to that of pre‐transplant patients with end‐stage lung disease, suggesting a quality of life improvement by lung transplantation. The presence of chronic lung allograft dysfunction (CLAD), a lower age at transplantation, and a longer time since transplantation were associated with lower HRQOL scores. Conclusion: This study underscores the generally favorable HRQOL experienced by pediatric lung transplant recipients.
Background/Objectives: Patients with chronic lung diseases, such as cystic fibrosis, were considered a risk group for a severe course of coronavirus disease 2019 at the beginning of the pandemic. However, mounting evidence suggests that this group may not face an elevated risk for a severe SARS-CoV-2 infection. Methods: Here, we present data on the incidence and clinical course of SARS-CoV-2 infections in a single pediatric CF centre in Austria. Clinical variables were analyzed for their potential impact on disease acquisition and severity. A total of 135 young people with CF were assessed from February 2020 until December 2022. Results: Eighty-four patients were infected with SARS-CoV-2, out of which nine patients reported re-infection, resulting in 93 SARS-CoV-2 infections. Most infections, 76/93 (82%), occurred during the period of omicron variant predominance. Higher body mass index and respiratory colonization with Haemophilus influenzae before the beginning of the pandemic were significantly associated with the risk of acquiring SARS-CoV-2 infection. All patients had an uncomplicated COVID-19 course, regardless of the SARS-CoV-2 variant and COVID-19 vaccine status at infection. The most frequent symptoms were rhinitis (53%), fatigue (49%), cephalea (43%), and fever (38%). Neither oxygen therapy nor hospitalization were needed for any of the patients. Lung function parameters (FEV1, FVC, FEF50, LCI), both in the early post-viral as well as late post-viral stages, were not significantly impacted by SARS-CoV-2 infections. No long-term post-COVID-19 effects were reported. Conclusions: Our single-centre experience suggests that the course of SARS-CoV-2 infections in children and adolescents with CF is primarily mild and uncomplicated.